Placebo to Mepolizumab

Phase 3

Placebo to Mepolizumab is one of 2 therapeutic programs targeting Eosinophilic Granulomatous Vasculitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Eosinophilic Granulomatous VasculitisActive, not recruiting

Eosinophilic Granulomatous VasculitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Eosinophilic Granulomatous Vasculitis

#DrugCompanyPhaseTrials

Fasenra

AstraZeneca

Phase 3

1 2

Placebo to Mepolizumab

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Eosinophilic Granulomatous Vasculitis

NCT04157348

Clinical

Trials by Indication[1]

Eosinophilic Granulomatous Vasculitis1 trial

A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04157348·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo to Mepolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo to Mepolizumab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AstraZeneca

Placebo to Mepolizumab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Eosinophilic Granulomatous Vasculitis1 trial

References

Drug Info

Quick Facts

Related News